Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Genetic Disease
Study Phase : Preclinical
Sponsor : Undisclosed
Deal Size : $14.5 million
Deal Type : Series D Financing
VECT-HORUS Completes Its €12 Million Fund-Raising Operation
Details : The funding round supports company's program focusing on identifying new vectors. Using the company's VECTrans® platform, nanoparticles of mRNA, as well as ASOs and siRNAs, can be vectorized in order to treat both diseases with a genetic component and c...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
January 20, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Genetic Disease
Highest Development Status : Preclinical
Sponsor : Undisclosed
Deal Size : $14.5 million
Deal Type : Series D Financing